Dr David Jackman on Clinical Pathways Discussion at PCOC® 2020

September 16, 2020

For this year's Patient-Centered Oncology Care® 2020 virtual conference, the discussion on clinical pathways will address how to optimize new data on innovations within oncology.

For this year's Patient-Centered Oncology Care® 2020 virtual conference, the discussion on clinical pathways will address how to optimize new data on innovations within oncology, said David Jackman, MD, senior physician and medical director of Clinical Pathways at the Dana-Farber Cancer Institute.

Transcript

AJMC®: What is the chief message you hope to convey to the participants at Patient-Centered Oncology Care 2020?

Jackman: Health care in this day and age is incredibly exciting, but it’s also incredibly complex. As we think about the torrent of data of new drug approvals and new studies coming forward, we need tools that can help us all sift through the noise and make sense of what belongs and what doesn’t, and how that changes in each given situation so that we can be not just nimble but granular.

Our pathways platform is one way of achieving this or at least moving in the right direction towards this. It’s part of what role pathways play at our institute, as well as other initiatives and other directives. We want that nimbleness to be around not only new medical information, but also frankly things that we learn from our patients as they encounter new side effects or other concerns around each individual regimen.

So, how can we take all of those lessons? The lessons we learned externally, the lessons we learned internally from our doctors and from our patients, and put that all in a nimble and efficient platform. So, that’s something that we’ve strived for with our pathways platform, and something that I think represents just yet 1 additional tool in our armament to wage this war on cancer.